- Home
- ABSI vs VSTM Comparison
ABSI vs VSTM Comparison
Compare ABSI & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABSI | VSTM |
|---|---|---|
| Founded | 2011 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 418.0M | 470.7M |
| IPO Year | 2021 | 2011 |
Fundamental Metrics
Financial Performance| Metric | ABSI | VSTM |
|---|---|---|
| Price | $2.65 | $5.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | $7.98 | ★ $14.50 |
| AVG Volume (30 Days) | ★ 3.0M | 1.6M |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.67 | 6.87 |
| EPS | ★ N/A | N/A |
| Revenue | $4,534,000.00 | ★ $10,000,000.00 |
| Revenue This Year | $10.72 | $208.96 |
| Revenue Next Year | $313.07 | $269.43 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 285.21 |
| 52 Week Low | $2.01 | $4.01 |
| 52 Week High | $5.23 | $11.25 |
Technical Indicators
Market Signals| Indicator | ABSI | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 43.39 | 40.80 |
| Support Level | $2.40 | $5.65 |
| Resistance Level | $2.79 | $6.81 |
| Average True Range (ATR) | 0.20 | 0.39 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 35.90 | 20.71 |
Price Performance
Historical ComparisonAbout ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.